Marika Crohns
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marika Crohns has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Hannu Alho
Department of Mental Health and Substance Abuse Services, National Institute for Health and Welfare, P.O. Box 30, FI-00271 Helsinki, Finland
5 shared publicationsPirkko Kellokumpu-Lehtinen
Department of Oncology, University of Tampere, P.O. Box 607, FI-33014 Tampereen yliopisto, Finland
5 shared publicationsSeppo Saarelainen
Department of Respiratory Medicine, Tampere University Hospital, P.O. Box 2000, FI-33521 Tampere, Finland
4 shared publicationsEeva Moilanen
2 shared publications- Hannu Kankaanranta
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
2 shared publications - Marina Erhola
Pirkanmaa Welfare district Tampere Finland
2 shared publications
Latest Publications
- 1 August 2009
- Published by Elsevier in Clinical Biochemistry
- Vol. 42 (12) , 1236-1245
Concurrent decline of several antioxidants and markers of oxidative stress during combination chemotherapy for small cell lung cancer
- 1 August 2009
- Published by Elsevier in Clinical Biochemistry
- Vol. 42 (12) , 1236-1245
Concurrent decline of several antioxidants and markers of oxidative stress during combination chemotherapy for small cell lung cancer
- 1 July 2009
- Published by Elsevier in Clinical Biochemistry
- Vol. 42 (10-11) , 1082-1090
Impact of radiotherapy and chemotherapy on biomarkers of oxidative DNA damage in lung cancer patients
- 1 July 2009
- Published by Elsevier in Clinical Biochemistry
- Vol. 42 (10-11) , 1082-1090
Impact of radiotherapy and chemotherapy on biomarkers of oxidative DNA damage in lung cancer patients
- Open Access
- 1 January 2009
- Published by Taylor & Francis in Free Radical Research
- Vol. 43 (7) , 646-657
Local and systemic oxidant/antioxidant status before and during lung cancer radiotherapy
To examine local and systemic oxidative status of lung cancer (LC) and oxidant effects of radiotherapy (RT), this study evaluated antioxidants and markers of oxidative and nitrosative stress in bronchoalveolar lavage (BAL) fluid and in the blood of 36 LC patients and 36 non-cancer controls at baseline and during and after RT for LC. LC patients had higher baseline serum urate, plasma nitrite and lower serum oxidized proteins than controls (p=0.016, p<0.001 and p=0.027, respectively), but BAL fluid oxidative stress markers were similar. RT tended to raise some antioxidants, however, significant increases were seen in serum urate, conjugated dienes and TBARS (p=0.044, p=0.034 and p=0.004, respectively) 3 months after RT. High urate at baseline may compensate against the oxidative stress caused by LC. RT shifts the oxidant/antioxidant balance towards lipid peroxidation, although the antioxidant defense mechanisms of the body appear to counteract the increased oxidative stress rather effectively.
- 1 January 2009
- Published by Taylor & Francis in Free Radical Research
- Vol. 43 (7) , 646-657
Open AccessLocal and systemic oxidant/antioxidant status before and during lung cancer radiotherapy
To examine local and systemic oxidative status of lung cancer (LC) and oxidant effects of radiotherapy (RT), this study evaluated antioxidants and markers of oxidative and nitrosative stress in bronchoalveolar lavage (BAL) fluid and in the blood of 36 LC patients and 36 non-cancer controls at baseline and during and after RT for LC. LC patients had higher baseline serum urate, plasma nitrite and lower serum oxidized proteins than controls (p=0.016, p<0.001 and p=0.027, respectively), but BAL fluid oxidative stress markers were similar. RT tended to raise some antioxidants, however, significant increases were seen in serum urate, conjugated dienes and TBARS (p=0.044, p=0.034 and p=0.004, respectively) 3 months after RT. High urate at baseline may compensate against the oxidative stress caused by LC. RT shifts the oxidant/antioxidant balance towards lipid peroxidation, although the antioxidant defense mechanisms of the body appear to counteract the increased oxidative stress rather effectively.
- 1 January 2009
- Published by Taylor & Francis in Free Radical Research
- Vol. 43 (10) , 965-974
Exhaled pentane as a possible marker for survival and lipid peroxidation during radiotherapy for lung cancer—a pilot study
To examine lipid peroxidation during radiotherapy (RT), exhaled pentane samples were collected from 11 lung cancer patients before RT and 30 and 120 min after the start of RT on days 1, 4 and 5 and at 30 and 40 Grays, if possible. Exhaled pentane samples were collected once from 30 healthy controls. Serum thiobarbituric-acid-reactive substances (TBARS) and conjugated dienes (CD) were obtained from patients on each exhaled air collection day. Lung cancer patients had higher exhaled pentane levels than controls (1.73 ng/L vs 0.83 ng/L, p=0.017). Exhaled pentane levels tended to decrease during the first RT day (p=0.075) and levels of CD decreased during the first week of RT (p=0.014). Higher pre-treatment pentane levels predicted better survival (p=0.003). Elevated exhaled pentane levels before RT may be due to the lipid peroxidation burden associated with cancer. The decrease of lipid peroxidation markers during RT may be attributable to enhanced antioxidant defense mechanisms.
- 1 January 2009
- Published by Taylor & Francis in Free Radical Research
- Vol. 43 (10) , 965-974
Exhaled pentane as a possible marker for survival and lipid peroxidation during radiotherapy for lung cancer—a pilot study
To examine lipid peroxidation during radiotherapy (RT), exhaled pentane samples were collected from 11 lung cancer patients before RT and 30 and 120 min after the start of RT on days 1, 4 and 5 and at 30 and 40 Grays, if possible. Exhaled pentane samples were collected once from 30 healthy controls. Serum thiobarbituric-acid-reactive substances (TBARS) and conjugated dienes (CD) were obtained from patients on each exhaled air collection day. Lung cancer patients had higher exhaled pentane levels than controls (1.73 ng/L vs 0.83 ng/L, p=0.017). Exhaled pentane levels tended to decrease during the first RT day (p=0.075) and levels of CD decreased during the first week of RT (p=0.014). Higher pre-treatment pentane levels predicted better survival (p=0.003). Elevated exhaled pentane levels before RT may be due to the lipid peroxidation burden associated with cancer. The decrease of lipid peroxidation markers during RT may be attributable to enhanced antioxidant defense mechanisms.